For the quarter ending 2026-03-31, RNAC has $288,391K in assets. $436,509K in debts. $118,641K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 118,641 | 125,139 | 143,384 | 160,324 |
| Accounts receivable | 261 | 1,115 | 722 | 354 |
| Prepaid expenses and other current assets | 3,137 | 3,022 | 3,154 | 2,717 |
| Total current assets | 122,039 | 129,276 | 147,260 | 163,395 |
| Property and equipment, net | 11,637 | 12,185 | 12,394 | 12,285 |
| Other assets | - | - | - | 5,551 |
| Right-of-use assets, net | 5,366 | 5,601 | 4,972 | 5,164 |
| In-process research and development asset | 93,900 | 93,900 | 150,600 | 150,600 |
| Goodwill | 48,163 | 48,163 | 48,163 | 48,163 |
| Long-term restricted cash | 1,735 | 1,735 | 1,735 | 1,735 |
| Investment | - | 0 | 2,000 | 2,000 |
| Long-term prepaid expenses and other assets | 5,551 | 5,551 | 5,551 | - |
| Total assets | 288,391 | 296,411 | 372,675 | 388,893 |
| Accounts payable | 1,598 | 1,288 | 2,225 | 454 |
| Accrued expenses and other current liabilities | 10,161 | 9,498 | 7,702 | 8,012 |
| Lease liabilities | 4,186 | 4,151 | 3,876 | 3,790 |
| Contingent value right liability | - | 0 | 0 | 0 |
| Total current liabilities | 15,945 | 14,937 | 13,803 | 12,256 |
| Lease liabilities, net of current portion | 7,669 | 8,525 | 8,727 | 9,559 |
| Warrant liability | 47 | 141 | 848 | 1,364 |
| Contingent value right liability | 405,900 | 392,100 | 369,000 | 352,100 |
| Deferred tax liabilities, net | 6,948 | 6,948 | 16,141 | 16,141 |
| Total liabilities | 436,509 | 422,651 | 408,519 | 391,420 |
| Preferred stock, value, issued-Series APreferred Stock | 0 | 0 | 0 | 0 |
| Preferred stock, value, issued-Series BPreferred Stock | 0 | 0 | 0 | 0 |
| Preferred stock, value, issued | 0 | 0 | 0 | 0 |
| Common stock, 0.0001 par value 350,000,000 shares authorized as of march 31, 2026 and december 31, 2025 28,544,728 and 26,011,106 shares issued and outstanding as of march 31, 2026 and december 31, 2025, respectively | 3 | 3 | 3 | 3 |
| Additional paid-in capital | 718,017 | 700,706 | 698,537 | 695,942 |
| Accumulated deficit | -861,555 | -822,373 | -729,797 | -693,895 |
| Accumulated other comprehensive loss | -4,583 | -4,576 | -4,587 | -4,577 |
| Total stockholders deficit | -148,118 | -126,240 | -35,844 | -2,527 |
| Total liabilities and stockholders deficit | 288,391 | 296,411 | 372,675 | 388,893 |
Cartesian Therapeutics, Inc. (RNAC)
Cartesian Therapeutics, Inc. (RNAC)